AstraZeneca PLC (AZN) - Stock Analysis
Last updated: Apr 12, 2026
Research Idea
Research content for general circulation. Not individualized advice.Ā Methodology & Disclosures
Recent high-impact drug catalysts (ENHERTU new 1L breast cancer approval, Baxdrostat NDA Priority Review) plus reiterated 2026 growth guidance and a ~19% 21-day price run with shares ~9% above the 21-day SMA and breaking out of the 188ā195 range support near-term continuation for a disciplined momentum trade.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ā¢ High profitability ā¢ Heavy R&D ā¢ Material leverage AstraZeneca combines very high margins and strong cash generation funded by heavy R&Dāsupporting durable earningsāwhile facing weak nearāterm liquidity, meaningful net debt, large intangibles and a premium valuation.
Price Behavior
Key Price Behavior Insights: ā¢ Above last-month SMA ā¢ Near-term resistance ā¢ Support cluster below Support Level: $200; $183ā$186 Resistance Level: $204ā$206; $207ā$208 AZN is in a short-term uptrendāclosing at $204.03 about 5% above last month's SMA (~$193.70) with moderate upside momentum but near-term resistance that could cap gains.
Sentiment & News
Key News Insights: ā¢ Oncology-led growth ā¢ Tozorakimab success ā¢ Patent/pricing risk AstraZeneca posted solid 2025 underlying growth led by oncology and rare diseases, boosted by tozorakimab phase III COPD wins and rising institutional/analyst support, but faces near-term Farxiga patent expiries and China pricing pressure.
AI Summary
AstraZeneca has transitioned from a steady cash-generator to a catalyst-driven growth betāits valuation now hinges on successful execution of 20+ lateāstage readouts and commercializing recent wins (e.g., tozorakimab), so investors must closely monitor upcoming Phase III readouts and Q1 guidance as binary catalysts for meaningful upside. Given rich multiples, elevated leverage and tight liquidity, a string of clinical or policy setbacks would likely trigger sharp multiple compression toward the 183ā186 support zone.
Description
AstraZeneca PLC is a global biopharmaceutical company engaged in the discovery, development, manufacture and commercialization of prescription medicines across oncology, cardiovascular, renal and metabolic (CVRM), respiratory, vaccines and rare diseases. Its commercial portfolio and pipeline span established brands and newer therapies for core therapeutic areas, and the company distributes products through primary and specialty care channels across the UK, Europe, the Americas, Asia, Africa and Australasia. Incorporated in 1992 and headquartered in Cambridge, UK, AstraZeneca maintains external R&D collaborations with partners such as Neurimmune AG, BenevolentAI, Lunit and Absci Corporation.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Feb 20 | Feb 27 | AZN | AstraZeneca PLC | Recent high-impact drug catalysts (ENHERTU new 1L breast cancer approval, Baxdrostat NDA Priority Review) plus reiterated 2026 growth guidance and a ~19% 21-day price run with shares ~9% above the 21-day SMA and breaking out of the 188ā195 range support near-term continuation for a disciplined momentum trade. | Closed | +2.1% |